Alembic Pharma shares fall 9% as EBITDA margins shrink in Q4 FY26
Synopsis
Alembic Pharmaceuticals' Q4 FY26 earnings delivered a paradox: net profit rose 29% but EBITDA margins collapsed more than 300 basis points to 12.3%, triggering a 9% single-session sell-off. With the stock already down 7% year-to-date and trading near its 52-week low, the market's verdict is clear — headline profit growth means little when operating efficiency is deteriorating.
Key Takeaways
Alembic Pharmaceuticals shares fell as much as 9 per cent on 18 May 2026 , closing down 7.42 per cent at ₹725.90 on the NSE .
EBITDA dropped 16.2 per cent year-on-year to ₹228 crore ; EBITDA margin contracted to 12.3 per cent from 15.4 per cent in Q4 FY25.
Consolidated net profit rose 29 per cent year-on-year to ₹202 crore ; revenue grew 4.4 per cent to ₹1,848 crore .
India-branded business grew 4 per cent to ₹568 crore ; international business rose 11 per cent to ₹564 crore .
Company received four ANDA approvals and launched six products in the US market during the quarter.
Market capitalisation stood at ₹14,142 crore ; stock is down approximately 7 per cent year-to-date.
Alembic Pharmaceuticals Limited shares tumbled as much as 9 per cent on Monday, 18 May 2026, after the Gujarat-based drugmaker posted weaker-than-expected operating performance for the March 2026 quarter (Q4 FY26), with a sharp contraction in EBITDA margins rattling investor confidence on the National Stock Exchange of India (NSE).
Stock Performance
The scrip hit an intra-day low of ₹710.70 on the NSE before recovering partially to close down 7.42 per cent, or ₹58.20, at ₹725.90. On a year-to-date basis, the stock has shed approximately 7 per cent, underperforming the broader pharma index.
The company's market capitalisation stood at ₹14,142 crore at close. The stock has traded between a 52-week high of ₹1,107.90 and a 52-week low of ₹635.80, underscoring the volatility that has dogged the counter over the past year.
Q4 FY26 Earnings at a Glance
On the headline numbers, Alembic Pharmaceuticals reported a 29 per cent year-on-year jump in consolidated net profit to ₹202 crore, up from ₹157 crore in Q4 FY25. Revenue from operations rose 4.4 per cent year-on-year to ₹1,848 crore, compared with ₹1,770 crore in the year-ago quarter.
However, the operating picture told a different story. EBITDA fell 16.2 per cent year-on-year to ₹228 crore from ₹272 crore, while the EBITDA margin narrowed sharply to 12.3 per cent from 15.4 per cent in the same period last year — a contraction of more than 300 basis points that analysts flagged as the primary concern.
Domestic and International Business
Alembic's India-branded business grew 4 per cent year-on-year to ₹568 crore, supported by traction in gynaecology, gastrology, ophthalmology, and animal healthcare segments. The company also launched two new products in the domestic market during the quarter.
On the international front, the business rose 11 per cent year-on-year to ₹564 crore, driven by the US formulations segment. Alembic launched six products in the US market during the quarter and received four ANDA approvals. Revenue from the ex-US generics business stood at ₹369 crore.
What the Numbers Signal
The divergence between a rising net profit and falling EBITDA points to one-off or below-the-line items inflating the bottom line — a pattern that markets typically discount. Notably, this margin compression comes at a time when several mid-cap pharma peers have reported improved operating leverage, making Alembic's Q4 FY26 print a relative outlier. The stock's proximity to its 52-week low suggests limited near-term downside cushion if margin pressure persists into FY27.
Investors will watch whether the company's US pipeline momentum — evidenced by four ANDA approvals and six launches — can translate into margin recovery in the quarters ahead.
Point of View
Not a 9% sell-off. But investors are right to look past the bottom line: EBITDA margins at 12.3% are well below the comfort zone for a mid-cap pharma with significant R&D and capex commitments. The structural question is whether rising US revenues — promising in isolation — can offset the cost pressures that are clearly building. Until Alembic demonstrates a credible path back to 15%-plus EBITDA margins, the stock's proximity to its 52-week low will remain a ceiling, not a floor.
NationPress
3 Jul 2026
Frequently Asked Questions
Why did Alembic Pharmaceuticals shares fall today?
Alembic Pharmaceuticals shares fell up to 9 per cent on 18 May 2026 after the company reported a sharp contraction in EBITDA margins for Q4 FY26, with operating profit declining 16.2 per cent year-on-year despite a rise in net profit. Investors reacted negatively to the weaker-than-expected operating performance.
What were Alembic Pharma's Q4 FY26 financial results?
The company posted a 29 per cent year-on-year rise in consolidated net profit to ₹202 crore, with revenue growing 4.4 per cent to ₹1,848 crore. However, EBITDA fell 16.2 per cent to ₹228 crore and EBITDA margins narrowed to 12.3 per cent from 15.4 per cent in Q4 FY25.
How is Alembic Pharmaceuticals performing in the US market?
Alembic's international business grew 11 per cent year-on-year to ₹564 crore in Q4 FY26, led by US formulations. The company launched six products in the US market and received four ANDA approvals during the quarter.
What is Alembic Pharmaceuticals' current market capitalisation?
As of 18 May 2026, Alembic Pharmaceuticals' market capitalisation stood at ₹14,142 crore. The stock closed at ₹725.90, down 7.42 per cent on the day, and is approximately 7 per cent lower on a year-to-date basis.
What should investors watch for Alembic Pharma going forward?
Investors will focus on whether Alembic can reverse the EBITDA margin compression — which fell over 300 basis points year-on-year — in FY27. The pace of US product launches and ANDA approvals, along with cost management in domestic operations, will be key indicators to track.
